Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

508.71
Delayed Data
As of Jul 28
 +0.30 / +0.06%
Today’s Change
325.35
Today|||52-Week Range
543.55
+38.58%
Year-to-Date
Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura
Jul 27 / Zacks.com - Paid Partner Content
Fears over a medical gold rush in cancer drug race
Jul 02 / FT.com - Paid Partner Content
Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?
Jul 26 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close508.41
Today’s open507.01
Day’s range499.04 - 513.42
Volume620,107
Average volume (3 months)943,422
Market cap$54.1B
Dividend yield--
Data as of 4:00pm ET, 07/28/2017

Growth & Valuation

Earnings growth (last year)+39.49%
Earnings growth (this year)+13.71%
Earnings growth (next 5 years)+19.00%
Revenue growth (last year)+18.44%
P/E ratio61.5
Price/Sales8.79
Price/Book12.12

Competitors

 Today’s
change
Today’s
% change
SHPGShire-1.07-0.63%
VRTXVertex Pharmaceutica...-2.04-1.31%
BAXBaxter International...+0.35+0.58%
AZNAstraZeneca+1.39+4.81%
Data as of 4:14pm ET, 07/28/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$3.16
Annual revenue (last year)$4.9B
Annual profit (last year)$895.5M
Net profit margin18.42%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Leonard S. Schleifer
Chief Financial Officer &
Senior VP-Finance
Robert E. Landry
Corporate headquarters
Tarrytown, New York

Forecasts